Document is current
Any future updates will be listed below
-
Authors
Ambjørn, Sara M. https://orcid.org/0000-0002-5571-1382
Duxin, Julien P.
Hertz, Emil P. T.
Nasa, Isha
Duro, Joana https://orcid.org/0000-0002-2608-4420
Kruse, Thomas
Lopez-Mendez, Blanca https://orcid.org/0000-0001-8541-4904
Rymarczyk, Beata
Cressey, Lauren E.
van Overeem Hansen, Thomas
Kettenbach, Arminja N. https://orcid.org/0000-0003-3979-4576
Oestergaard, Vibe H. https://orcid.org/0000-0002-1633-0560
Lisby, Michael https://orcid.org/0000-0002-4830-5247
Nilsson, Jakob https://orcid.org/0000-0003-4100-1125
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF14CC0001)
- License Information
-
More Information
Article History
Received: 4 May 2021
Accepted: 13 September 2021
First Online: 30 September 2021
Competing interests
: J.N. is on the scientific advisory board for Orion Pharma. T.v.O.H. has received lecture honoraria from Pfizer. The remaining authors declare no competing interests.
